← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Molecular Insight Pharmaceuticals, Inc.
Cambridge, MA
$11,481,045
Total funding
22
Grants
Funding over time
peak $2.3M · FY2005–12$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$11,481,045 · 22
By mechanism
R44$7,684,129 · 6
R43$2,820,052 · 13
R41$677,184 · 2
R21$299,680 · 1
Investigators at Molecular Insight Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Systemic radiotherapy for metastatic melanomas: Innovation of a novel radiopharma$911,810
R44 · FY2009 · CA
Development of a Molecular Targeting Agent for PSMA to Diagnose Metastatic Prosta$801,864
R44 · FY2010 · CA
Early Clinical Testing for Melanin Targeting Radio-therapeutic agent in melanoma$737,540
R44 · FY2011 · CA
Systemic radiotherapy for metastatic melanomas: Innovation of a novel radiopharma$722,670
R44 · FY2011 · CA
Developing Nanodosing of Iobenguane I 131 for Radiotherapy$573,884
R44 · FY2006 · CA
Early Clinical Testing for Melanin Targeting Radio-therapeutic agent in melanoma$559,294
R44 · FY2010 · CA
A kit based PET agent: edotreotide Ga 68 for clinical imaging of somatostatin rec$542,102
R44 · FY2012 · CA
Nanodosing: A path to higher sensitivity and lower toxicity pharmaceuticals$496,373
R44 · FY2009 · CA
Development of a Molecular Targeting Agent for PSMA to Diagnose Metastatic Prosta$488,453
R44 · FY2009 · CA
Nanodosing: A path to higher sensitivity and lower toxicity pharmaceuticals$485,175
R44 · FY2008 · CA
Novel single amino acid analogs as chelators for Tc99m$377,374
R41 · FY2003 · AI
Developing Nanodosing of Iobenguane I 131 for Radiotherapy$351,359
R44 · FY2007 · CA
Labeled inhibitors for angiotensin converting enzyme$337,713
R43 · FY2004 · HL
Systemic radiotherapy for metastatic melanomas: Innovation of a novel radiopharma$331,449
R44 · FY2008 · CA
Development of a Molecular Targeting Agent for PSMA to Diagnose Metastatic Prosta$327,410
R44 · FY2011 · CA
Novel glutamate conjugates for radiotargeting PSMA$327,235
R43 · FY2004 · EB
Norepinephrine Transporters: Targets for ADHD$301,412
R43 · FY2004 · HD
Size-Dependent Uptake of Tc(I)-Labeled RGD Analogs$299,810
R41 · FY2005 · CA
Development of a kit based PET molecular imaging agent: edotreotide Ga 68 for so$262,993
R43 · FY2010 · CA
A Molecular targeting agent for systemic radiotherapy of metastatic Prostate Canc$243,101
R43 · FY2010 · CA